Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + anlotinib
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebrelimab + anlotinib is a combination therapy comprising a programmed cell death ligand 1 (PD-L1) inhibitor and a multi-target tyrosine kinase inhibitor (TKI). Adebrelimab (SHR-1316), developed by Jiangsu Hengrui Pharmaceuticals, is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7.1), thereby enhancing T-cell mediated immune responses against tumor cells. Anlotinib (AL3818), developed by Chia Tai Tianqing, is an oral small molecule that inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor proliferation, including VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. This combination is primarily being investigated for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with clinical research often led by institutions such as Shanghai Pulmonary Hospital. The rationale for the combination lies in the potential synergistic effects of anti-angiogenic therapy in modulating the tumor microenvironment to enhance the efficacy of immune checkpoint inhibitors.
- Brand names
- AdelyFukanghua
- Other names
- SHR-1316 + AL3818
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on adebrelimab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + anlotinib.